TY - JOUR
T1 - Use of Artificial Intelligence and Machine Learning for Discovery of Drugs for Neglected Tropical Diseases
AU - Winkler, David A.
N1 - Funding Information:
The current business model for new drug development favors developed countries with populations or governments able to pay for drugs, allowing the very high development costs (median 2020 cost estimated to be US$1-1.3Bn) to be recouped by companies (Wouters et al., 2020). This is one of the major reasons why most tropical diseases are “neglected.” Given the immense burden of disease, there is clearly an urgent need to develop better treatments for NTDs. One way to achieve this is through the intervention of charitable government funds like the US NIH and DoD, European Union, Medicines for Malaria venture, Bill and Melinda Gates Foundation, and the Wellcome Trust. One aim of the London Declaration of Neglected Tropical Diseases (Molyneux, 2017), inspired by the World Health Organization 2020 roadmap to eradicate or prevent transmission for neglected tropical diseases (https://unitingtocombatntds.org/resources/ who-roadmap-ntds/), is to “advance research and development through partnerships and provision of funding to find treatments and interventions for NTDs. Global warming that increases the range of some NTDs, and the pandemic risk that infectious diseases originating from tropical regions pose, is driving renewed interest and urgency on disease preparedness that includes preemptive development of drugs. These programs and factors should drive increased interest and investment in discovery of drugs for NTDs in the future.
Publisher Copyright:
© Copyright © 2021 Winkler.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/3/15
Y1 - 2021/3/15
N2 - Neglected tropical diseases continue to create high levels of morbidity and mortality in a sizeable fraction of the world’s population, despite ongoing research into new treatments. Some of the most important technological developments that have accelerated drug discovery for diseases of affluent countries have not flowed down to neglected tropical disease drug discovery. Pharmaceutical development business models, cost of developing new drug treatments and subsequent costs to patients, and accessibility of technologies to scientists in most of the affected countries are some of the reasons for this low uptake and slow development relative to that for common diseases in developed countries. Computational methods are starting to make significant inroads into discovery of drugs for neglected tropical diseases due to the increasing availability of large databases that can be used to train ML models, increasing accuracy of these methods, lower entry barrier for researchers, and widespread availability of public domain machine learning codes. Here, the application of artificial intelligence, largely the subset called machine learning, to modelling and prediction of biological activities and discovery of new drugs for neglected tropical diseases is summarized. The pathways for the development of machine learning methods in the short to medium term and the use of other artificial intelligence methods for drug discovery is discussed. The current roadblocks to, and likely impacts of, synergistic new technological developments on the use of ML methods for neglected tropical disease drug discovery in the future are also discussed.
AB - Neglected tropical diseases continue to create high levels of morbidity and mortality in a sizeable fraction of the world’s population, despite ongoing research into new treatments. Some of the most important technological developments that have accelerated drug discovery for diseases of affluent countries have not flowed down to neglected tropical disease drug discovery. Pharmaceutical development business models, cost of developing new drug treatments and subsequent costs to patients, and accessibility of technologies to scientists in most of the affected countries are some of the reasons for this low uptake and slow development relative to that for common diseases in developed countries. Computational methods are starting to make significant inroads into discovery of drugs for neglected tropical diseases due to the increasing availability of large databases that can be used to train ML models, increasing accuracy of these methods, lower entry barrier for researchers, and widespread availability of public domain machine learning codes. Here, the application of artificial intelligence, largely the subset called machine learning, to modelling and prediction of biological activities and discovery of new drugs for neglected tropical diseases is summarized. The pathways for the development of machine learning methods in the short to medium term and the use of other artificial intelligence methods for drug discovery is discussed. The current roadblocks to, and likely impacts of, synergistic new technological developments on the use of ML methods for neglected tropical disease drug discovery in the future are also discussed.
KW - artificial intelligence
KW - drug discovery
KW - machine learning
KW - neglected tropical diseases
KW - structure-property relationships
UR - https://www.scopus.com/pages/publications/85103335119
U2 - 10.3389/fchem.2021.614073
DO - 10.3389/fchem.2021.614073
M3 - Review Article
AN - SCOPUS:85103335119
SN - 2296-2646
VL - 9
JO - Frontiers in Chemistry
JF - Frontiers in Chemistry
M1 - 614073
ER -